Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Drops By 97.9%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 45 shares, a drop of 97.9% from the February 26th total of 2,126 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 10,225 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 10,225 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. raised its position in shares of Invesco Biotechnology & Genome ETF by 1.8% during the third quarter. Raymond James Financial Inc. now owns 8,078 shares of the company’s stock valued at $564,000 after buying an additional 141 shares during the last quarter. NewEdge Advisors LLC grew its stake in Invesco Biotechnology & Genome ETF by 18.1% during the fourth quarter. NewEdge Advisors LLC now owns 1,043 shares of the company’s stock valued at $86,000 after acquiring an additional 160 shares in the last quarter. Comerica Bank increased its holdings in Invesco Biotechnology & Genome ETF by 86.2% in the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after acquiring an additional 175 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Invesco Biotechnology & Genome ETF by 74.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after acquiring an additional 245 shares during the last quarter. Finally, Newman Dignan & Sheerar Inc. lifted its stake in Invesco Biotechnology & Genome ETF by 3.0% in the 4th quarter. Newman Dignan & Sheerar Inc. now owns 10,070 shares of the company’s stock worth $827,000 after purchasing an additional 298 shares in the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of Invesco Biotechnology & Genome ETF stock traded up $1.85 during trading hours on Wednesday, hitting $78.35. The company’s stock had a trading volume of 3,161 shares, compared to its average volume of 7,594. The company has a market cap of $251.50 million, a PE ratio of 20.44 and a beta of 0.79. The business has a 50 day moving average price of $80.78 and a two-hundred day moving average price of $78.14. Invesco Biotechnology & Genome ETF has a 12-month low of $54.52 and a 12-month high of $85.73.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.